Abstract:Hyperuricemia (HUA) is a common metabolic disorder characterized by the accumulation of uric acid in the joints, which leads to the formation of urate crystals and the development of gout. Additionally, HUA can trigger other health issues. Despite the diverse urate-lowering drugs available on the market, they often come with side effects, including renal damage. Live biotherapeutic products are considered safer and more effective for treating hyperuricemia, with the additional benefits of regulating the gut microbiome. This article primarily discusses the research progress in developing live biotherapeutics for treating hyperuricemia based on synthetic biology. It focuses on the construction and expression of functional modules, such as the degradation of purine precursors, the creation of new purine metabolic pathways, the optimization of urate oxidase expression, and the enhancement of uric acid oxidation reactions. This review aims to provide new insights for the development of live biotherapeutic products for hyperuricemia.
